Article

Predictive Biomarkers for Bevacizumab: Are We There Yet?

Pathology, The University of Texas MD Anderson Cancer Center.
Clinical Cancer Research (Impact Factor: 8.19). 04/2013; DOI: 10.1158/1078-0432.CCR-12-3409
Source: PubMed

ABSTRACT Therapy targeting VEGF has become the standard of care in several solid malignancies. Early investigations attempting to identify predictive markers for the efficacy of therapy failed to identify any predictive markers that could help oncologist decide who should, and more importantly, who should not receive VEGF-targeted therapies. However, there has been renewed interest in predictive biomarkers for VEGF-targeted therapies especially in light of the fact that the US Food and Drug Administration withdrew approval for use of bevacizumab, an antibody to VEGF, in patients with metastatic breast cancer. In a recent publication in the Journal of Clinical Oncology, investigators identified circulating VEGF and tumor neuropilin-1 expression as potential predictive biomarkers for bevacizumab. In this perspective, we provide a critical evaluation of the utility of these markers, and the need for validation in prospective clinical trials.

0 Followers
 · 
67 Views
  • The Lancet 10/2013; 383(9911). DOI:10.1016/S0140-6736(13)61892-9 · 45.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Artículo de revisión 236 Rev Venez Oncol 2013;25(4):236-254 RESUMEN Los anticuerpos terapéuticos representan uno de los grupos más importantes de nuevos medicamentos para el tratamiento del cáncer. Gracias a los resultados alentadores observados en la clínica y a su relativa baja toxicidad, los anticuerpos se han convertido en el segmento de mayor crecimiento de las grandes empresas farmacéuticas. Sus propiedades terapéuticas, así como también sus limitaciones, son permanentemente evaluadas en ensayos clínicos alrededor del mundo. Esta dinámica acelerada de desarrollo y evaluación va en paralelo con los elevados costos de estos reactivos tanto para el paciente como para los sistemas de salud pública. Esta revisión tiene por finalidad organizar y actualizar la información generada en el ámbito de la terapia de tumores sólidos con anticuerpos terapéuticos y servir como herramienta crítica de consulta y documentación para clínicos e investigadores en ejercicio y en formación.
    Revista Venezolana de Oncologia 12/2013; 25(4):236-254.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Tumor growth requires induction of an angiogenic program, and targeting of this program with antiangiogenic drugs shows an impact on tumor progression. However, although they are effective at reducing angiogenesis, these therapies have not produced widespread or enduring clinical benefit, which openly exposes their limitations. Here, we describe the current limitations of these therapies, including the known mechanisms and current controversies. Further, we present some of the recent approaches to predict these limitations and strategies to overcome them. With the development of meaningful predictive biomarkers and effective treatments that impede these limitations, longer and more robust efficacies will be achieved for a wider population of patients.
    Cancer Discovery 12/2013; 4(1). DOI:10.1158/2159-8290.CD-13-0199 · 15.93 Impact Factor